Altshuler Shaham’s UroGen Pharma URGN Stock Holding History

Altshuler Shaham’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-22,801	Closed	-$187K	–	536
2022 Q2	$187K	Hold	22,801	–	–	﹤0.01%	133
2022 Q1	$199K	Sell	22,801 -19,700	-46%	-$154K	﹤0.01%	219
2021 Q4	$404K	Hold	42,501	–	–	﹤0.01%	206
2021 Q3	$719K	Hold	42,501	–	–	0.01%	186
2021 Q2	$649K	Hold	42,501	–	–	﹤0.01%	190
2021 Q1	$828K	Buy	42,501 +19,000	+81%	+$403K	0.01%	109
2020 Q4	$423K	Hold	23,501	–	–	0.01%	116
2020 Q3	$453K	Hold	23,501	–	–	0.01%	127
2020 Q2	$614K	Hold	23,501	–	–	0.02%	90
2020 Q1	$419K	Sell	23,501 -2,671	-10%	-$72.2K	0.02%	100
2019 Q4	$873K	Hold	26,172	–	–	0.02%	77
2019 Q3	$620K	Buy	26,172 +280	+1%	+$9.15K	0.02%	86
2019 Q2	$931K	Buy	25,892 +1,194	+5%	+$44K	0.04%	82
2019 Q1	$912K	Hold	24,698	–	–	0.04%	87
2018 Q4	$1.06M	Buy	+24,698	New	+$1.11M	0.05%	82

Other funds holding URGN

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

WCM

Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Altshuler Shaham's URGN Position: Q3 2022 in Review

Altshuler Shaham sold out of UroGen Pharma (URGN) in Q3 2022, closing a stake of 22,801 shares — an estimated $187K sold.

Altshuler Shaham first reported a position in URGN in Q4 2018 and held it in 15 quarters. The position peaked at $1.06M in Q4 2018. 60 funds tracked by Wall St. Rank hold URGN as of Q3 2022.

Altshuler Shaham reported no remaining UroGen Pharma position as of Q3 2022 after selling out during the quarter.
Altshuler Shaham sold 22,801 UroGen Pharma shares in Q3 2022, an estimated $187K.
Altshuler Shaham first reported a position in UroGen Pharma in Q4 2018 and held it in 15 quarters.
Altshuler Shaham's UroGen Pharma position peaked at $1.06M in Q4 2018.
60 funds tracked by Wall St. Rank held UroGen Pharma as of Q3 2022.

Based on Altshuler Shaham's 13F filing for Q3 2022, filed 14 Nov 2022.